Cargando…
Vaccines for COVID‐19
Since the emergence of COVID‐19, caused by the SARS‐CoV‐2 virus at the end of 2019, there has been an explosion of vaccine development. By 24 September 2020, a staggering number of vaccines (more than 200) had started preclinical development, of which 43 had entered clinical trials, including some a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597597/ https://www.ncbi.nlm.nih.gov/pubmed/32935331 http://dx.doi.org/10.1111/cei.13517 |
_version_ | 1783602397593993216 |
---|---|
author | Tregoning, J. S. Brown, E. S. Cheeseman, H. M. Flight, K. E. Higham, S. L. Lemm, N.‐M. Pierce, B. F. Stirling, D. C. Wang, Z. Pollock, K. M. |
author_facet | Tregoning, J. S. Brown, E. S. Cheeseman, H. M. Flight, K. E. Higham, S. L. Lemm, N.‐M. Pierce, B. F. Stirling, D. C. Wang, Z. Pollock, K. M. |
author_sort | Tregoning, J. S. |
collection | PubMed |
description | Since the emergence of COVID‐19, caused by the SARS‐CoV‐2 virus at the end of 2019, there has been an explosion of vaccine development. By 24 September 2020, a staggering number of vaccines (more than 200) had started preclinical development, of which 43 had entered clinical trials, including some approaches that have not previously been licensed for human vaccines. Vaccines have been widely considered as part of the exit strategy to enable the return to previous patterns of working, schooling and socializing. Importantly, to effectively control the COVID‐19 pandemic, production needs to be scaled‐up from a small number of preclinical doses to enough filled vials to immunize the world’s population, which requires close engagement with manufacturers and regulators. It will require a global effort to control the virus, necessitating equitable access for all countries to effective vaccines. This review explores the immune responses required to protect against SARS‐CoV‐2 and the potential for vaccine‐induced immunopathology. We describe the profile of the different platforms and the advantages and disadvantages of each approach. The review also addresses the critical steps between promising preclinical leads and manufacturing at scale. The issues faced during this pandemic and the platforms being developed to address it will be invaluable for future outbreak control. Nine months after the outbreak began we are at a point where preclinical and early clinical data are being generated for the vaccines; an overview of this important area will help our understanding of the next phases. |
format | Online Article Text |
id | pubmed-7597597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75975972020-11-05 Vaccines for COVID‐19 Tregoning, J. S. Brown, E. S. Cheeseman, H. M. Flight, K. E. Higham, S. L. Lemm, N.‐M. Pierce, B. F. Stirling, D. C. Wang, Z. Pollock, K. M. Clin Exp Immunol Article Collection: COVID‐19 Since the emergence of COVID‐19, caused by the SARS‐CoV‐2 virus at the end of 2019, there has been an explosion of vaccine development. By 24 September 2020, a staggering number of vaccines (more than 200) had started preclinical development, of which 43 had entered clinical trials, including some approaches that have not previously been licensed for human vaccines. Vaccines have been widely considered as part of the exit strategy to enable the return to previous patterns of working, schooling and socializing. Importantly, to effectively control the COVID‐19 pandemic, production needs to be scaled‐up from a small number of preclinical doses to enough filled vials to immunize the world’s population, which requires close engagement with manufacturers and regulators. It will require a global effort to control the virus, necessitating equitable access for all countries to effective vaccines. This review explores the immune responses required to protect against SARS‐CoV‐2 and the potential for vaccine‐induced immunopathology. We describe the profile of the different platforms and the advantages and disadvantages of each approach. The review also addresses the critical steps between promising preclinical leads and manufacturing at scale. The issues faced during this pandemic and the platforms being developed to address it will be invaluable for future outbreak control. Nine months after the outbreak began we are at a point where preclinical and early clinical data are being generated for the vaccines; an overview of this important area will help our understanding of the next phases. John Wiley and Sons Inc. 2020-10-18 2020-11 /pmc/articles/PMC7597597/ /pubmed/32935331 http://dx.doi.org/10.1111/cei.13517 Text en © 2020 The Authors. Clinical and Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Collection: COVID‐19 Tregoning, J. S. Brown, E. S. Cheeseman, H. M. Flight, K. E. Higham, S. L. Lemm, N.‐M. Pierce, B. F. Stirling, D. C. Wang, Z. Pollock, K. M. Vaccines for COVID‐19 |
title | Vaccines for COVID‐19 |
title_full | Vaccines for COVID‐19 |
title_fullStr | Vaccines for COVID‐19 |
title_full_unstemmed | Vaccines for COVID‐19 |
title_short | Vaccines for COVID‐19 |
title_sort | vaccines for covid‐19 |
topic | Article Collection: COVID‐19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597597/ https://www.ncbi.nlm.nih.gov/pubmed/32935331 http://dx.doi.org/10.1111/cei.13517 |
work_keys_str_mv | AT tregoningjs vaccinesforcovid19 AT brownes vaccinesforcovid19 AT cheesemanhm vaccinesforcovid19 AT flightke vaccinesforcovid19 AT highamsl vaccinesforcovid19 AT lemmnm vaccinesforcovid19 AT piercebf vaccinesforcovid19 AT stirlingdc vaccinesforcovid19 AT wangz vaccinesforcovid19 AT pollockkm vaccinesforcovid19 |